Licensing & partnership
AbbVie licenses Nxera's oral EP4 agonist for IBD for up to $1.47 billion
AbbVie gains worldwide rights to NXE0033744, a gut-selective oral EP4 receptor agonist for inflammatory bowel disease. Nxera gets $100 million upfront, as much as $1.37 billion more in milestones, and tiered royalties, subject to antitrust clearance. A finished Phase 1 study supported the candidate's gut selectivity and target engagement.
Written by Gosset from public sources. Source types: News article. Sources are available to Gosset users. Log in to see them.